Viatris (VTRS) Q2 2026 earnings review
Raised Guidance Masked by Heavy GAAP Losses and Supply Chain Disruptions
Viatris delivered a solid operational beat in Q2, prompting management to raise all full-year financial guidance midpoints. Revenue grew 5% YoY, and Adjusted EBITDA accelerated 10%, driven largely by a 21% surge in Greater China and 6% growth in Brands. The company also reached its gross leverage target of 2.9x ahead of schedule. However, the non-GAAP narrative heavily masks GAAP realities. A $177.8M non-cash impairment related to the Tyrvaya divestiture dragged the company into a U.S. GAAP net loss of $119M. Furthermore, recurring manufacturing issues in India (Nashik) are forcing a $100M-$150M revenue headwind into the second half of the year.
🐂 Bull Case
Greater China revenue accelerated by 21% YoY to $713.8M, outperforming all other segments. This robust demand profile supports the upgraded FY26 guidance.
The company reduced its gross leverage ratio to 2.9x, hitting its long-term target (2.8x-3.2x) while concurrently returning ~$550M to shareholders via dividends and aggressive share repurchases.
🐻 Bear Case
Selling global rights to Tyrvaya triggered a severe $177.8M write-down, driving an unappealing U.S. GAAP Net Loss of $119M. Stripping out 'adjustments' shows a much weaker bottom-line reality.
The Nashik facility fire and subsequent FDA Form 483 will cost $100M-$150M in H2 revenues. Following 2025's massive Indore facility struggles, Viatris's global supply chain remains an operational liability.
⚖️ Verdict: ⚪
Neutral. The operational momentum and raised guidance reflect genuine stabilization in the base business and success in China. However, chronic facility issues, heavy reliance on non-GAAP adjustments to show profitability, and lagging Emerging Markets prevent a fully bullish stance.
Key Themes
Greater China Segment Accelerating Outperformance
Greater China is officially Viatris's primary growth engine, accelerating to 21% reported growth YoY (16% operational) and generating $713.8M. E-commerce investments and strong brand equity are pulling the weight for the entire company, vastly offsetting weakness in JANZ and Emerging Markets.
Nashik Facility Disruption Plagues H2 Outlook
Following a fire in February and an FDA Form 483 in May, intermittent production suspensions at the Nashik, India plant will drag H2 total revenues down by $100M-$150M. While guidance was still raised, this recurring theme of Indian manufacturing struggles (mirroring 2025's Indore facility crisis) exposes a critical fragility in Viatris's supply chain.
Pipeline Delivering Concrete Commercial Milestones
The company's pivot to innovative assets is showing tangible results. The FDA approved Gwyn Lo (contraceptive patch) for commercial availability later this year, and MR-107A-02 (fast-acting meloxicam) secured a PDUFA date of December 27, 2026. These targeted, specific product innovations are critical to the company's objective of generating $450M-$550M in new product revenue this year.
GAAP vs Non-GAAP Reality Gap
The positive narrative relies almost entirely on Adjusted EBITDA and Adjusted EPS. The actual U.S. GAAP net loss was $118.8M, primarily dragged down by a non-cash charge of $177.8M to right-size the Tyrvaya asset prior to its sale to Harrow, Inc. Constantly writing down assets to 'unlock value' contradicts the narrative of high-quality portfolio management.
Emerging Markets and JANZ Decelerating
While China booms, other international segments are contracting. Emerging Markets fell 2% YoY to $542.3M due to continued supply constraints in the lower-margin ARV business. Meanwhile, the JANZ segment (Japan, Australia, New Zealand) decelerated 3% YoY to $296.1M, continuing to suffer from structural, macro government price regulations.
Aggressive Capital Structure Reset
Management stabilized the balance sheet. Viatris repaid ~$900M of maturing debt, refinanced the remainder with 4.250% Euro notes, and drove the gross leverage ratio down to 2.9x—solidly within their 2.8x-3.2x target range. This enabled ~$270M in opportunistic share repurchases at an average price of $16.42.
Other KPIs
Stable. Free Cash Flow excluding transaction and restructuring costs nearly doubled from $241M in Q2 2025 to $449M in Q2 2026, pointing to vastly improved operational cash conversion despite the heavy restructuring footprint.
Accelerating. Up 6% YoY on a reported basis (4% operational), indicating excellent durability and pricing power within their established, higher-margin portfolio, particularly in global markets outside of the US.
Guidance
Accelerating. Management raised the midpoint by $50M to $14.75B. This implies confidence in absorbing the $100M-$150M Nashik manufacturing hit in H2 entirely through outperformance in Greater China and Brands.
Accelerating. The midpoint was raised heavily by $100M to $4.4B. This reflects strong cost-control execution and gross margin stability despite ongoing restructuring operations.
Accelerating. Midpoint raised from $2.40 to $2.52, materially assisted by lower outstanding share count due to aggressive $270M buybacks and stronger underlying EBITDA.
Stable. The midpoint of $2.20B was raised slightly from $2.15B. The actual reported operating cash flow will be closer to $2.0B due to ~$600M in transaction and restructuring cash drains.
Key Questions
Systemic Supply Chain Risk
Following the Indore facility struggles in 2025, Nashik is now creating a $100M-$150M H2 headwind due to a fire and an FDA Form 483. What structural changes are being implemented to stop these single-point-of-failure disruptions from recurring annually?
Tyrvaya Economics
You divested Tyrvaya to Harrow for $30M upfront, triggering a $177.8M write-down. Can you explain the rapid value destruction on this asset, and does it change your calculus for future in-market M&A acquisitions?
ARV Portfolio Margin Profile
Emerging Markets declined 2% due to supply constraints in the ARV business. Given the low-margin nature of this portfolio, is it diluting your focus, and are you actively considering divesting it as part of your ongoing strategic review?
China Decoupling Risk
Greater China is keeping the growth narrative afloat with 21% growth. Given macro geopolitical risks and internal anti-corruption campaigns in the Chinese healthcare sector, how durable is this 20%+ run-rate over the next 12-24 months?